Literature DB >> 18084800

[Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference].

P Kirchhof1, A Goette, G Hindricks, S Hohnloser, K-H Kuck, T Meinertz, U Ravens, G Steinbeck, G Breithardt.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18084800     DOI： 10.1007/s00399-007-0581-x

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN： 0938-7412


× No keyword cloud information.
  101 in total

1.  A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA).

Authors:  Paulus Kirchhof; Gerold Mönnig; Kristina Wasmer; Achim Heinecke; Günter Breithardt; Lars Eckardt; Dirk Böcker
Journal:  Eur Heart J       Date:  2005-02-25       Impact factor: 29.983

2.  Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.

Authors:  Paul T Akins; Harvey A Feldman; Robert G Zoble; David Newman; Stefan G Spitzer; Hans-Christoph Diener; Gregory W Albers
Journal:  Stroke       Date:  2007-01-25       Impact factor: 7.914

3.  The use of quinidine in cardioversion.

Authors:  M Rossi; B Lown
Journal:  Am J Cardiol       Date:  1967-02       Impact factor: 2.778

4.  Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone.

Authors:  T Van Noord; I C Van Gelder; B A Schoonderwoerd; H J Crijns
Journal:  Am J Cardiol       Date:  2000-12-15       Impact factor: 2.778

5.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

6.  Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I.

Authors:  X Jouven; M Desnos; C Guerot; P Ducimetiere
Journal:  Eur Heart J       Date:  1999-06       Impact factor: 29.983

7.  Value of different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation.

Authors:  Christopher Piorkowski; Hans Kottkamp; Hildegard Tanner; Richard Kobza; Jens Cosedis Nielsen; Arash Arya; Gerhard Hindricks
Journal:  J Cardiovasc Electrophysiol       Date:  2005-12

8.  An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation.

Authors:  M Brignole; C Menozzi; M Gasparini; M G Bongiorni; G L Botto; R Ometto; P Alboni; C Bruna; A Vincenti; R Verlato
Journal:  Eur Heart J       Date:  2002-06       Impact factor: 29.983

9.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

10.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.